Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Measles Vaccine in HCW (MV-COVID19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04357028
Recruitment Status : Suspended (Failure of subject recruitment)
First Posted : April 22, 2020
Last Update Posted : December 22, 2020
Sponsor:
Information provided by (Responsible Party):
Ahmed Mukhtar, Kasr El Aini Hospital

Brief Summary:

Till now, mortality reports among children below 9 years remains extremely low despite that the incidence of death toll is high and exceeding 50,000 patients among older population, One speculation for lower SARS infectivity is that cross-protective antibodies against measles vaccine ( MV). In mice susceptible to measles virus, recombinant MV induced the highest titers of neutralizing antibodies and fully protected immunized animals from intranasal infectious challenge with SARS-CoV,

The primary objective of the present study is to determine the benefit of measles vaccine in health care professional to decrease the incidence of COVID-19.

We Hypothesized that, measles vaccine may lower the incidence of serologically proven SARS-CoV-2 infection and reported respiratory illness


Condition or disease Intervention/treatment Phase
Covid19 Drug: Measles-Mumps-Rubella Vaccine Drug: Placebos Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial)
Actual Study Start Date : July 13, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Measles

Arm Intervention/treatment
Experimental: MMR vaccine
0.5 ml subcutaneous of MMR vaccine will be injected in posterior triceps aspect of upper arm
Drug: Measles-Mumps-Rubella Vaccine
Measles mumps Rubella vaccine is a weak attenuated life vaccine

Placebo Comparator: Control
0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm
Drug: Placebos
0.5 ml subcutaneous of saline will be injected in posterior triceps aspect of upper arm




Primary Outcome Measures :
  1. COVID-19 disease incidence [ Time Frame: Time Frame: Measured over the 6 months following randomization ]
    Number of participants with asymptomatic or mild COVID-19 disease defined as fever (using self-reported questionnaire), plus at least one sign or symptom of respiratory disease including cough, runny/blocked nose (using self-reported questionnaire), plus positive SARS-Cov-2 test (PCR or serology)


Secondary Outcome Measures :
  1. SARS-CoV-2 pneumonia [ Time Frame: Time Frame: Measured over the 6 months following randomization ]
    Number of pneumonia cases (abnormal chest X-ray) (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

  2. Critical care admission duration with SARS-CoV-2 [ Time Frame: Time Frame: Measured over the 6 months following randomization ]
    Number of days admitted to critical care (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test

  3. Oxygen therapy with SARS-CoV-2 [ Time Frame: Time Frame: Measured over the 6 months following randomization ]
    Need for oxygen therapy (using self-reported questionnaire and/or medical/hospital records) associated with a positive SARS-CoV-2 test



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age 18-50 years old
  • Subjects who are willing to comply with the requirements of the study protocol and scheduled visits (for example, completion of the subject diary, return for follow-up visits) and who are willing to make themselves available for the duration of the study with access to a consistent means of telephone contact

Exclusion Criteria:

  • acute severe illness
  • recent receipt of a blood product
  • history of thrombocytopenia
  • Pregnant females
  • any chronic medical condition
  • Any participant receiving any immune suppressive medication
  • Immunocompromised staff
  • Participants who have egg allergy
  • Participants who care for immune compromised hosts
  • Participants who test positive for COVID-19 serology prior to randomization

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04357028


Locations
Layout table for location information
Egypt
Cairo University Hospital
Cairo, Egypt, 11559
Sponsors and Collaborators
Kasr El Aini Hospital
Layout table for additonal information
Responsible Party: Ahmed Mukhtar, professor of anesthesia and intensive care, Kasr El Aini Hospital
ClinicalTrials.gov Identifier: NCT04357028    
Other Study ID Numbers: N-30-2020
First Posted: April 22, 2020    Key Record Dates
Last Update Posted: December 22, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Ahmed Mukhtar, Kasr El Aini Hospital:
MMR vaccine, Respiratory failure,
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases